Jemperli

Chemical Namedostarlimab
Dosage FormProgrammed death receptor-1 (PD-1)–blocking antibodies
Drug ClassProgrammed death receptor-1-blocking antibodies
SystemMultiple
CompanyGlaxoSmithKline
Approval Year2021

Indication

  • For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
  • For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Document TitleYearSource
Jemperli (dostarlimab-gxly) Prescribing Information.2022GlaxoSmithKline LLC, Philadelphia, PA
Document TitleYearSource
Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update.2022Journal of Clinical Oncology
Drug updated on 7/5/2023

More on this drug: Clinical Trials